Predictive Technology Group, Inc.’s (PRED) Subsidiary Provides a Sponsorship at 4th Annual Perinatal Stem Cell Society Congress

SALT LAKE CITY, March 05, 2018 -- Predictive Biotech, Inc., a wholly owned subsidiary of Predictive Technology Group, Inc. (OTCPINK:PRED) provided a sponsorship at the 4^th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT on March 1-2, 2018.

Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc. presented his topic during the March 1-2, 2018 4th Annual Perinatal Stem Cell Society Congress, Salt Lake City, UT, titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?” www.predictivebiotech.com www.predictivetechnologygroup.com

​In 2013, the Perinatal Stem Cell Society, Inc. a non-profit organization was founded on the basic principle that stem cells from perinatal tissues contain enormous, untapped life potential to treat many diseases and disorders.  Perinatal stem cell sources include: amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue.

Dr. Doug Schmid, Chief Science and Lab Officer, at Predictive Biotech, Inc., presented an oral presentation to the society titled: “Wharton’s Jelly: A Perinatal Cytokine Reservoir?”

Dr. Schmid received his Ph.D. in Physiology from the University of Utah School of Medicine in Salt Lake City, Utah. He completed four years of post-doctoral training at the University of Utah Medical School and five years as a Research Associate at the University of Utah Medical School as a cellular biologist.  Dr. Schmid has 23 years of experience in primary cell culture, tissue processing and cryogenic storage of cells and tissues. After working at the University of Utah, from 2009 to present, Dr. Schmid has established, implemented, and supervised the operational aspects of several tissue companies, including the recovery, quality control, processing, and distribution of tissue.  He is passionate about quality and vitality of physiological products and the vast benefits they deliver.

Predictive Technology Group, Inc. wholly owned subsidiary, Predictive Biotech, Inc. is in the business of developing advancements in human cell and tissue products.  Data collected in collaboration with other research institutes and clients are the cornerstone in Predictive Biotech’s product development.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and [email protected].

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK:PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED is exploring possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com, and www.predbiotech.com

Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:

Rich Kaiser
YES INTERNATIONAL
757-306-6090
[email protected]

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/6c2ff288-c076-4c1f-99b6-fd5d91ca9220